Keywords: |
unclassified drug; single nucleotide polymorphism; bone metastasis; conference paper; cancer radiotherapy; nuclear magnetic resonance imaging; prostate specific antigen; metastasis; green fluorescent protein; bisphosphonic acid derivative; diagnostic imaging; vasculotropin inhibitor; risk assessment; monoclonal antibody; protein tyrosine kinase inhibitor; cancer hormone therapy; prostate cancer; prostate-specific antigen; prostatic neoplasms; prostate specific membrane antigen; prostatectomy; bone; nuclear magnetic resonance spectroscopy; heterozygosity loss; antiandrogen; bicalutamide; antineoplastic agents, hormonal; receptors, androgen; tyrosine kinase; fragility fracture; epidermal growth factor receptor kinase; zoledronic acid; optical coherence tomography; atrasentan; endothelin 1; humans; human; male; priority journal; endothelin a receptor antagonist; monoclonal antibody huj591
|